HER3 Binding Polypeptides for Targeted Cancer Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies targeting EGFR and HER2 receptors face challenges due to the large size of monoclonal antibodies, which hinder tissue distribution and penetration, and the long in vivo half-life leading to poor tumor-to-blood contrasts in molecular imaging, while bispecific monoclonal antibodies binding to two separate targets are complex to produce effectively.
Innovation Solution
Development of HER3 binding polypeptides with specific amino acid sequences that bind to the extracellular domain of HER3, allowing for high specificity and affinity, potentially used in combination with HER2 or EGFR binding polypeptides to create bispecific ligands for enhanced targeting and imaging of HER3-expressing cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to target EGFR and HER2 receptors, then therapeutic effect is achieved, but tissue distribution and penetration are hindered due to large molecule size
Solution Approach 1:
The patent divides the monoclonal antibody into smaller functional fragments (such as Fab fragments, Fv fragments, or single-chain variable fragments) that retain the binding specificity for EGFR or HER2 while reducing the overall molecular size. This segmentation allows the therapeutic agent to penetrate tissues more effectively while maintaining therapeutic activity.
Solution Approach 2:
The patent extracts only the essential binding and functional components from the full monoclonal antibody structure, removing the Fc region and other non-essential portions. This extraction creates smaller molecular entities that improve tissue penetration while preserving the core therapeutic function of target binding and signal interruption.
2Measurement precision
If monoclonal antibodies are used for molecular imaging, then targeting is achieved, but tumor-to-blood contrast is poor due to long in vivo half-life
Solution Approach 1:
The patent employs short-lived imaging agents based on smaller molecular fragments or peptide conjugates that clear rapidly from the blood circulation. These short-lived agents provide high tumor-to-blood contrast during the imaging window and then disappear from the bloodstream, allowing repeated imaging studies without accumulation of background signal.
Solution Approach 2:
The patent changes the molecular size and clearance parameters of the imaging agent by using smaller fragments or conjugating to peptides with different pharmacokinetic properties. This parameter change reduces the in vivo half-life and improves the temporal resolution of imaging, enabling better differentiation between tumor signal and background blood signal.
3Adaptability or versatility
If bispecific monoclonal antibodies binding to two separate targets are developed, then dual targeting capability is achieved, but production complexity increases
Solution Approach 1:
The patent segments the bispecific antibody into separate binding modules that can be produced independently and then assembled. Each module targets a specific receptor (EGFR or HER2), and the modules are connected through standardized linkers or fusion techniques, simplifying the production process compared to generating fully recombinant bispecific antibodies de novo.
Solution Approach 2:
The patent creates a universal platform of modular binding fragments that can be combined in different configurations to target multiple receptors. These modular units serve multiple functions: they can bind to different targets, be conjugated to different payloads, and be produced using standardized protocols, thereby reducing overall production complexity despite achieving dual targeting capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The HER3 binding polypeptides demonstrate strong binding affinity to HER3, enabling improved targeting and imaging of HER3-expressing cells, potentially leading to more effective cancer therapy and diagnostics by overcoming the limitations of traditional monoclonal antibodies.
Implementation Method 1
The HER3 binding polypeptides demonstrate strong binding affinity to HER3, enabling improved targeting and imaging of HER3-expressing cells
Data Source
AI summary
The disclosure provides a HER3 binding polypeptide, comprising a HER3 binding motif, BM, which motif consists of the amino acid sequence selected from i) EX2X3X4A X6X7EIW X11LPNL X16X17X18QX20 X21AFIX25 X26LX28D, and ii) an amino acid sequence which has at least 90% identity to the sequence defined in i), wherein the polypeptide binds to the extra-cellular domain of HER3. Also provided is a bispecific ligand having binding affinity for HER3 and for HER2, or for HER3 and for EGFR, and comprising a HER3. binding polypeptide as defined herein and a HER2 binding polypeptide or a EGFR binding polypeptide.